How Safe Are GlaxoSmithKline plc & Royal Dutch Shell Plc’s 6%+ Dividend Yields?

Can you trust GlaxoSmithKline plc (LON: GSK) and Royal Dutch Shell Plc’s (LON: RDSB) dividend yields?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Two of the FTSE 100’s dividend stalwarts, GlaxoSmithKline (LSE: GSK) and Royal Dutch Shell (LSE: RDSB), have both recently hit multi-year lows on concerns that neither company will be able to afford its dividend payout this year. 

Indeed, at time of writing Royal Dutch Shell is trading at 1,783p, a five-year low, and the company’s dividend yield currently stands at 6.8%. Similarly, Glaxo’s shares are trading at a three-year low and support a yield of 6%, more than twice the FTSE 250’s average yield of 2.4%. 

However, in today’s low interest rate environment, you’d be hard pressed to find other investments that support similar yields, making Glaxo and Shell perfect stocks for the income investor in my view. 

Should you invest £1,000 in The Sage Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if The Sage Group Plc made the list?

See the 6 stocks

The question is, are these market-beating dividend yields too good to be true?

A risky sport 

Chasing yield can be a risky sport. You shouldn’t buy a stock just because it has a high dividend yield without first assessing the underlying business and sustainability of the payout.

And the most common way of assessing the sustainability of any dividend payout is to use the dividend cover ratio. Dividend cover provides an indication of how many times a company’s dividend payout is covered by earnings or profit generated from operations.

Unfortunately, Shell and Glaxo are cutting it fine when it comes to dividend cover. Based on current forecasts, Shell’s dividend payout is set to total 121.50p per share this year, compared to earnings per share of 128.1p, leaving little room for error. 

Glaxo’s dividend payout will amount to 80p per share this year, although according to current forecasts the company is only expected to earn 77.2p per share. In other words, looking at the numbers, it seems as if Glaxo can’t afford its dividend payout. 

Looking past the numbers 

The figures may suggest that Glaxo and Shell will be forced to slash their dividend payouts, but other factors suggest otherwise. 

For example, Shell has paid and increased its dividend every year since the end of the Second World War, and that’s an illustrious record management won’t want to break any time soon.

Luckily, the company has the capacity to maintain its payout at present levels in the short term as earnings fall. Shell’s balance sheet is relatively debt-free — net gearing is 14.3% — and analysts expect earnings to rise 24% next year, which should push the dividend cover back to a more conservative 1.3x. 

Glaxo’s management has stated that the company’s dividend payout will be maintained at 80p per share for the next few years. While I’m always sceptical about management forecasts, I’m inclined to believe that this will be the case, and Glaxo’s payout isn’t going to be cut any time soon. 

City projections suggest that the company’s dividend will be covered by earnings next year, and management expect steady earnings growth in the “mid-to-high single digits” from 2016 to the end of the decade. 

The bottom line

So overall, Glaxo and Shell’s dividends look to be safe for the time being, presenting a once-in-a-lifetime opportunity for income investors. 

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, the Vodafone share price could turn £5,000 into…

Could the Vodafone share price jump by 30% over the next 12 months? Zaven Boyrazian takes a closer look at…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Prediction: 12 months from now, the Aviva share price could turn £5,000 into…

The Aviva share price tumbled in the tariff-induced market turmoil, but could this have created a new buying opportunity for…

Read more »

Investing Articles

Prediction: 12 months from now, the BAE share price could turn £5,000 into…

With EU defence spending on the rise, the BAE Systems' share price could surge… right? Not necessarily. Zaven Boyrazian digs…

Read more »

Investing Articles

Up more than 50% in a month! What’s going on with the Greatland Gold (GGP) share price?

The Greatland Gold (GGP) share price has been the best performer on the FTSE AIM 100 index over the past…

Read more »

Investing Articles

Prediction: 12 months from now, the IAG share price could turn £5,000 into…

Zaven Boyrazian explores how high the IAG share price can fly over the next 12 months and what factors investors…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

Prediction: 12 months from now, the BP share price could turn £5,000 into…

The BP share price crashed in April following the aftermath of US tariffs and tumbling oil prices. But is this…

Read more »

Investing Articles

14.2% dividend yield! Is this FTSE income stock worth considering in 2025?

This clean energy trust offers the highest dividend yield in the FTSE 350 right now, but is the double-digit payout…

Read more »

Investing Articles

£5,000 invested in the S&P 500 at the start of 2025 is now worth…

2025 has been a bumpy ride for the S&P 500, tumbling towards a correction before falling further on tariff news…

Read more »